By Connor Hart
Shares of Sana Biotechnology surged after the company released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes.
The stock more than tripled, up 265% to $6.02, in after-hours trading Tuesday. Shares ended the regular session 5.7% lower, at $1.65, putting them down 68% in the last 52 weeks.
The Seattle company said it transplanted its treatment, UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the use of any immunosuppression.
Results of the study at four weeks after cell transplantation demonstrate the survival and function of pancreatic beta cells as measured by the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin, the company said.
The study identified no safety issues, and the hypoimmune-modified islet cells evaded immune responses, according to Sana.
"We achieved our goals for the study, identifying no safety issues as well as demonstrating survival, function and evasion of immune detection of HIP-modified primary pancreatic islet cells transplanted intramuscularly with no immunosuppression," Chief Executive Steve Harr said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 07, 2025 18:00 ET (23:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。